The safety of novel drugs used to treat irritable bowel syndrome (Q38199522)

30 August 2017

0 references

The safety of novel drugs used to treat irritable bowel syndrome (English)

1 reference

30 August 2017

3

1 reference

30 August 2017

Shilan Mozaffari

1

1 reference

30 August 2017

Shekoufeh Nikfar

series ordinal

2

1 reference

30 August 2017

language of work or name

English

0 references

publication date

26 March 2014

1 reference

Expert Opinion on Drug Safety

30 August 2017

published in

1 reference

30 August 2017

volume

13

1 reference

30 August 2017

issue

5

1 reference

30 August 2017

page(s)

625-638

1 reference

Proteomic analysis of colonic mucosa in a rat model of irritable bowel syndrome

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Implications of melatonin therapy in irritable bowel syndrome: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Immune activation in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Probiotics use to treat irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Herbal medicines for the management of irritable bowel syndrome: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Effects of Hypericum perforatum extract on rat irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Efficacy and tolerability of renzapride in irritable bowel syndrome: a meta-analysis of randomized, controlled clinical trials including 2528 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Metabolic and toxicological considerations for the latest drugs used to treat irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Lubiprostone induced ischemic colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

The pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of linaclotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Efficacy of linaclotide for patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Two randomized trials of linaclotide for chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Novel evidence for hypersensitivity of visceral sensory neural circuitry in irritable bowel syndrome patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Influence of asimadoline, a new kappa-opioid receptor agonist, on tubular water absorption and vasopressin secretion in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Effects of asimadoline, a kappa-opioid agonist, on satiation and postprandial symptoms in health

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

The effect of fluvoxamine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Rifaximin therapy for patients with irritable bowel syndrome without constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Effect of renzapride on transit in constipation-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Identification of patients with non-d, non-C irritable bowel syndrome and treatment with renzapride: an exploratory, multicenter, randomized, double-blind, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Evaluation of harm in the pharmacotherapy of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Linaclotide: a novel approach to the treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.902932

10.1517/14740338.2014.902932

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference